Maxim Positive on Onconova Therapeutics (ONTX) Following Q2 Report; Notes Accelerating INSPIRE Enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/19/2026

1. NVDA
2. HD
3. AMLX
4. METC
5. SPY
6. DOO
7. ARGX
8. KLAR
9. INFQ

Go back to Maxim Positive on Onconova Therapeutics (ONTX) Following Q2 Report; Notes Accelerating INSPIRE Enrollment

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

August 15, 2016 7:01 AM EDT

NEWTOWN, Pa., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.

We are encouraged by the progress of our global Phase 3 trial of our lead product candidate, rigosertib, for patients with myelodysplastic syndromes (MDS).  The INSPIRE trial is actively enrolling patients in the U.S., Europe and Japan, and we have recently opened trial sites in... More